Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clifutinib Besylate in Relapsed/Refractory AML
NCT04827069Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- May 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clifutinib in acute myeloid leukemia (AML) (6 cohorts), sponsored by Sunshine Lake Pharma. Primary endpoint: Maximum Tolerated Dose. Started May 2018; status: completed.
02
Drugs
clifutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04827069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827069.